Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05643001 · ClinicalTrials.gov registry record · NA
Precision Clinical and Genetic Tools for Brain Health in Hemorrhagic Stroke
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 340
- Enrollment target
NCT05643001: Completed NA study, sponsored by Massachusetts General Hospital.
NCT05643001 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 340 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05643001, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 340 participants
- Enrollment target
Study Summary
The overall goal of this study is to increase health care provider awareness for common risk factors and comorbidities in patients with hemorrhagic stroke that are related to impaired brain health, to ultimately improve patients management and associated outcomes. The specific objective is to test the performance and effectiveness of a custom electronic health record (EHR)-based notification module at time of index hospitalization and at follow-up for hemorrhagic stroke survivors, before disparities in access to outpatient care may limit opportunities to intervene. The investigators hypothesize that notification of health care providers through the EHR will increase measurements of low-density lipoprotein (LDL) and glycated hemoglogbin A1c (HbA1c) and increase evaluation and management rates for obstructive sleep apnea and hearing impairment.
Interventions
- OTHER In-patient and out-patient electronic health record alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2025-03-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05643001
The ClinicalTrials.gov registry entry for NCT05643001 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which In-patient and out-patient electronic health record alert is the first listed.
NCT05643001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05643001 about?
NCT05643001 is a clinical study titled "Precision Clinical and Genetic Tools for Brain Health in Hemorrhagic Stroke". The overall goal of this study is to increase health care provider awareness for common risk factors and comorbidities in patients with hemorrhagic stroke that are related to impaired brain health, to ultimately improve patients management and associated outcomes. The specific objective is to test t...
What is the current status of trial NCT05643001?
This trial is currently completed. It is a NA study. The enrollment target is 340 participants. The study started on 2023-03-15. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT05643001?
The interventions under investigation include: In-patient and out-patient electronic health record alert (OTHER).
Who is sponsoring clinical trial NCT05643001?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.